Fine Foods & Pharmaceuticals N.T.M. S.p.A. Company Profile

Background

Fine Foods & Pharmaceuticals N.T.M. S.p.A., established in 1984, is an Italian independent Contract Development & Manufacturing Organisation (CDMO) specializing in the development and manufacturing of contract products for the pharmaceutical, nutraceutical, and cosmetics industries. The company is headquartered in Verdellino, Italy, and is listed on the STAR segment of the MTA of Borsa Italiana under the ticker symbol FF.

Mission: To provide high-quality, innovative, and sustainable manufacturing solutions for the pharmaceutical, nutraceutical, and cosmetics sectors, fostering long-term partnerships with clients.

Vision: To be a leading CDMO recognized for excellence in product quality, research and development, and commitment to environmental, social, and governance (ESG) principles.

Primary Area of Focus: Contract manufacturing and development of oral solid forms, including powders, granules, tablets, and capsules, as well as cosmetic products such as oral hygiene items, skin care products, deodorants, body cleansing products, shampoos, conditioners, and perfumery items.

Industry Significance: Fine Foods plays a pivotal role in the pharmaceutical and nutraceutical sectors by offering comprehensive manufacturing services that enable clients to bring products to market efficiently and with high quality. The company's commitment to sustainability and innovation enhances its reputation as a reliable partner in the industry.

Key Strategic Focus

Fine Foods' strategic focus encompasses several core objectives:

Core Objectives: Enhance production capacity, expand market share, and strengthen customer relationships through high-quality manufacturing services.

Specific Areas of Specialization: Development and manufacturing of solid oral forms for pharmaceuticals and nutraceuticals, and a diverse range of cosmetic products.

Key Technologies Utilized: Fluid bed granulation technology for producing instant soluble powders and effervescent forms.

Primary Markets or Conditions Targeted: Pharmaceutical and nutraceutical companies seeking contract manufacturing services, and cosmetic brands requiring production of personal care products.

Financials and Funding

Fine Foods has demonstrated consistent financial growth:

Total Revenue: €244 million in 2024, with a 21.7% increase compared to 2023.

Adjusted EBITDA: 64.2% increase in 2023 compared to the previous year.

Market Capitalization: €239.62 million as of December 17, 2025.

Recent Funding: On October 30, 2025, Fine Foods signed a medium-to-long-term loan agreement with Intesa Sanpaolo S.p.A. for €30 million, due in 2029, to support the Group's three-year investment plan.

Pipeline Development

Fine Foods is actively expanding its production capabilities:

Pharmaceutical Production Expansion: Construction of a new 10,000 sqm building at the Brembate pharmaceutical plant, with production expected to commence in 2026.

Nutraceutical Plant Expansion: Acquisition of approximately 21,000 sqm adjacent to the current nutraceutical plant, with an investment of approximately €4 million, to increase production capacity.

Technological Platform and Innovation

Fine Foods distinguishes itself through:

Proprietary Technologies: Advanced fluid bed granulation technology for producing instant soluble powders and effervescent forms.

Significant Scientific Methods: Implementation of sustainable practices and adherence to international standards for environmental and social governance.

Leadership Team

The leadership team comprises:

Pietro Oriani: General Manager, appointed on August 2, 2024.

Marco Francesco Eigenmann: Chairman and CEO, who announced his resignation on September 13, 2024, due to personal reasons.

Competitor Profile

Market Insights and Dynamics:

The contract manufacturing market for pharmaceuticals, nutraceuticals, and cosmetics is experiencing growth, driven by increasing demand for outsourcing production to specialized CDMOs. This trend is expected to continue, offering opportunities for companies like Fine Foods to expand their market share.

Competitor Analysis:

Key competitors include:

Frontage Holdings: A global contract research and manufacturing organization.

Dishman Carbogen Amcis: A global provider of integrated services to the pharmaceutical industry.

Anhui Wanbang Pharmaceutical Technology Ltd: A Chinese company specializing in pharmaceutical manufacturing.

Fine Foods differentiates itself through its commitment to sustainability, innovation, and high-quality manufacturing services.

Strategic Collaborations and Partnerships

Fine Foods has strengthened its market position through:

Acquisition of Pharmatek-PMC: Expanding into the cosmetics, biocides, and medical devices industries.

Transition to Borsa Italiana’s STAR Segment: Enhancing visibility and access to a broader range of investors.

Operational Insights

Fine Foods' strategic considerations include:

Market Position: Leveraging its position as a leading CDMO in Italy to expand internationally.

Competitive Advantages: Utilizing advanced manufacturing technologies and a strong commitment to sustainability to differentiate from competitors.